Abstract:We established proof of concept for activating pyruvate kinase in sickle cell disease (SCD) as a viable therapeutic approach. Mitapivat, a PK activator, improved hematologic parameters, increased oxygen affinity, and reduced sickling in patients with SCD anemia. Polymerization of deoxygenated hemoglobin S (HbS) underlies the pathophysiology of sickle cell disease (SCD). In activating red blood cell pyruvate kinase and glycolysis, mitapivat (AG-348) increases adenosine triphosphate (ATP) levels and decreases the 2,3-diphosphoglycerate (2,3-DPG) concentration, an upstream precursor in glycolysis. Both changes have therapeutic potential for patients with SCD. Here, we evaluated the safety and tolerability of multiple ascending doses of mitapivat in adults with SCD (HbSS) with no recent blood transfusions or changes in hydroxyurea (HU) or L-glutamine therapy. Seventeen subjects were enrolled, 1 subject was withdrawn shortly after starting the study. Sixteen subjects completed 3 ascending dose levels of mitapivat (5 mg, 20 mg and 50 mg, twice daily (BID)) for 2 weeks each; following a protocol amendment, the dose was escalated to 100 mg BID in 9 subjects. Mitapivat was well-tolerated at all dose levels, with the most common treatment-emergent adverse events (AEs) being insomnia, headache, and hypertension. Six serious AEs (SAEs) included 4 vaso-occlusive crises (VOCs), non-VOC-related shoulder pain, and a pre-existing pulmonary embolism. Two VOCs occurred during drug taper and were possibly drug-related; no other SAEs were drug-related. Mean hemoglobin increase at the 50 mg BID dose level was 1.2 g/dL, with 9/16 (56.3%) patients achieving a hemoglobin response of ≥ 1 g/dL increase compared to baseline. Mean reductions in hemolytic markers and dose-dependent decreases in 2,3-DPG and increases in ATP were also observed. This study provides proof of concept that mitapivat has disease-modifying potential in patients with SCD. (Investigator-sponsor; ClinicalTrials.gov NCT04000165).

The search for pyruvate kinase-R activators; from a HTS screening hit via an impurity to the discovery of a lead series

Erythrocyte pyruvate kinase activation in red cell disorders

High-throughput Screening of Novel Pyruvate Dehydrogenase Kinases Inhibitors and Biological Evaluation of Their in Vitro and in Vivo Antiproliferative Activity.

Activating pyruvate kinase improves red blood cell integrity by reducing band 3 tyrosine phosphorylation.

Pyruvate kinase activators: targeting red cell metabolism in thalassemia

High Resolution Crystal Structure of the Pyruvate Kinase Tetramer in Complex with the Allosteric Activator Mitapivat/AG-348

P1565: Mitapivat Improves Ineffective Erythropoiesis And Reduces Iron Overload In Patients With Pyruvate Kinase Deficiency

Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease

Discovery of a Fluorogenic Probe for In Situ Pyruvate Kinase M2 Isoform (PKM2) Labeling through Chemoselective S N Ar with a Binding Site Lysine Residue

Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease

Sulfone-based human liver pyruvate kinase inhibitors – Design, synthesis and in vitro bioactivity

Beyond adenosine triphosphate: unveiling the pleiotropic effects of pyruvate kinase activation in sickle cell anemia

Targeting pyruvate kinase M2 for the treatment of kidney disease

Discovery, Synthesis And Biological Evaluation Of Substituted Urea: New Activators Of Heme Regulated Inhibitor

New Pyridin-3-ylmethyl Carbamodithioic Esters Activate Pyruvate Kinase M2 and Potential Anticancer Lead Compounds.

High-resolution Molecular Dynamics Simulations of the Pyruvate Kinase Muscle Isoform 1 and 2 (PKM1/2)

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1h-pyrazol-1-yl)methyl)phosphonate (BMS-820132)

A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1 H-pyrazol-1-yl)methyl)phosphonate (BMS-820132)

Computational Study on New Natural Compound Inhibitors of Pyruvate Dehydrogenase Kinases

Development of an HTS-Compatible Assay for the Discovery of Ulk1 Inhibitors